Discover
AYTU
Aytu BioPharma, Inc.
2.18
1 x 1.56
1 x 2.76
bid
ask
+
0.03
1.16%
12:04 PM
timesize
| Ytd | -16.15% | |
| 1y | -4.80% |
2.12
day range
2.20
1.65
52 week range
3.07
| Open | 2.20 | Prev Close | 2.15 | Low | 2.12 | High | 2.20 | Mkt Cap | 22.75M |
| Vol | 2.40K | Avg Vol | 38.37K | EPS | -4.61 | P/E | N/A | Forward P/E | 3.57 |
| Beta | -1.40 | Short Ratio | 10.45 | Inst. Own | 34.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 2.29 | 200-d Avg | 2.37 | 1yr Est | 8.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-12 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-11-13 | 2024-09 | 0 | -0.2 | N/A | N/A |
| 2024-09-26 | 2024-06 | 0 | -0.82 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -0.52 | N/A | N/A |
| 2024-02-14 | 2023-12 | 0 | -0.04 | N/A | N/A |
| 2023-11-14 | 2023-09 | 0 | -1.48 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2023-08-09 | Maxim Group | Upgrade | Buy | |
| 2023-05-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-06-13 | DISBROW JOSHUA R. | Chief Executive Officer | 71.59K | Purchase |
| 2024-11-05 | DOCKERY CARL C | Director | 10.44K | Stock Award(Grant) |
| 2024-11-05 | JAIN ABHINAV | Director | 9.50K | Stock Award(Grant) |
| 2024-11-05 | LIU VIVIAN H | Director | 9.82K | Stock Award(Grant) |
| 2024-06-13 | NANTAHALA CAPITAL MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-09-29 | PYSZCZYMUKA GREG | Officer | 23.19K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Nantahala Capital Management, LLC | 1.09M | 1.63M | 17.67% |
| 2024-09-29 | Stonepine Capital Management, LLC | 500.96K | 751.44K | 8.15% |
| 2024-09-29 | Armistice Capital, LLC | 236.00K | 354.00K | 3.84% |
| 2024-09-29 | Renaissance Technologies, LLC | 74.72K | 112.08K | 1.22% |
| 2024-09-29 | Geode Capital Management, LLC | 45.10K | 67.65K | 0.73% |
| 2024-09-29 | Vanguard Group Inc | 27.89K | 41.83K | 0.45% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 33.27K | 49.91K | 0.54% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 27.89K | 41.83K | 0.45% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.05K | 12.08K | 0.13% |
| 2024-07-30 | DFA U.S. Targeted Value Portfolio | 6.16K | 9.24K | 0.10% |
| 2024-07-30 | Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 3.38K | 5.07K | 0.05% |
| 2024-07-30 | DFA U.S. Micro Cap Series | 3.23K | 4.84K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2023-01-06 |
| 1 : 10 | 2020-12-09 |
| 1 : 20 | 2018-08-13 |
| 1 : 20 | 2017-08-29 |
| 1 : 12 | 2016-07-01 |
| 82 : 1000 | 2015-06-10 |